Cargando…

RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

We observed that high-dose methylprednisolone (HDMP) and rituximab (R) was well tolerated and had promising activity when used in combination to treat patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). This prompted us to evaluate the use of these agents in frontline therapy. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castro, Januario E., James, Danelle F., Sandoval-Sus, Jose D., Jain, Sonia, Bole, Janet, Rassenti, Laura, Kipps, Thomas J.
Formato:	Texto
Lenguaje:	English
Publicado:	2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761991/ https://www.ncbi.nlm.nih.gov/pubmed/19693094 http://dx.doi.org/10.1038/leu.2009.133

Ejemplares similares

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
por: Castro, J E, et al.
Publicado: (2014)

Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
por: Pileckyte, Regina, et al.
Publicado: (2019)

Lack of Allelic Exclusion in B Cell Chronic Lymphocytic Leukemia
por: Rassenti, Laura Z., et al.
Publicado: (1997)

Chronic lymphocytic leukaemia/small lymphocytic lymphoma treatment with rituximab and high‐dose methylprednisolone, revisited
por: Vagos Mata, Ana, et al.
Publicado: (2021)

Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells
por: Hasan, Md Kamrul, et al.
Publicado: (2018)

Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia
por: Schwaederlé, M, et al.
Publicado: (2013)

The spectrum of use of rituximab in chronic lymphocytic leukemia
por: Tedeschi, Alessandra, et al.
Publicado: (2010)

Rituximab for the treatment of patients with chronic lymphocytic leukemia
por: Gentile, M, et al.
Publicado: (2010)

High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia
por: Ghia, Emanuela M., et al.
Publicado: (2022)

Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism
por: Hasan, Md Kamrul, et al.
Publicado: (2020)

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells
por: Hasan, M K, et al.
Publicado: (2017)

B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities
por: Kluckova, Katarina, et al.
Publicado: (2022)

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
por: Wallace, Danielle S., et al.
Publicado: (2023)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib
por: Yu, J, et al.
Publicado: (2017)

Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter’s Syndrome
por: Heyman, Benjamin M., et al.
Publicado: (2022)

Role of rituximab in first-line treatment of chronic lymphocytic leukemia
por: Bryan, Jeffrey, et al.
Publicado: (2011)

Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia
por: Šimkovič, Martin, et al.
Publicado: (2015)

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
por: Kashyap, Manoj K., et al.
Publicado: (2017)

Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia
por: Kämpjärvi, Kati, et al.
Publicado: (2014)

Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
por: Barbier, Michaela, et al.
Publicado: (2021)

Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia
por: Murphy, Elizabeth J., et al.
Publicado: (2017)

Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
por: Kashyap, Manoj K., et al.
Publicado: (2015)

Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab
por: Forero, Andres, et al.
Publicado: (2013)

Response of multifocal acquired demyelinating sensorimotor neuropathy associated with atypical chronic lymphocytic leukemia to rituximab therapy
por: Jain, Ankur, et al.
Publicado: (2020)

Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia
por: Heyman, Benjamin M., et al.
Publicado: (2022)

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2019)

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
por: Shadman, Mazyar, et al.
Publicado: (2019)

Potent Fluorinated Agelastatin Analogues for Chronic Lymphocytic Leukemia: Design, Synthesis, and Pharmacokinetic Studies
por: Stout, E. Paige, et al.
Publicado: (2014)

Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells
por: Yu, J, et al.
Publicado: (2017)

Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias
por: Nikitin, Eugene, et al.
Publicado: (2023)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2015)

Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives
por: Sriwijitalai, Won, et al.
Publicado: (2019)

Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab
por: Ito, Yuta, et al.
Publicado: (2018)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Woyach, Jennifer A, et al.
Publicado: (2009)

HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia
por: Pagotto, Sara, et al.
Publicado: (2019)

Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
por: Rosenwald, Andreas, et al.
Publicado: (2001)

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
por: Walker, Janek S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dajbpgb8pgqp2079mqjtisfp84